Detail akcie Organon Rg-WI online

Business Summary: Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Organon & Co revenues decreased 2% to $4.71B. Net income decreased 48% to $392M. Revenues reflect Cardiovascular segment decrease of 17% to $864M, Respiratory segment decrease of 16% to $640M, Europe and Canada segment decrease of 10% to $1.21B, Asia Pacific and Japan segment decrease of 7% to $752M. Net income also reflects Restructuring costs increase from $23M to $88M (expense), Selling.